Fig 1: IL-27 expression is increased by SPY1 immunization(A) Mice were intranasally immunized with SPY1 plus CT or PBS plus CT weekly for 1 month and specimens were collected for analysis on day 28.(B) mRNA expression levels of the IL-27 subunits p28, EBI3, the IL-35 subunits p35, and the IL-27 receptor subunit WSX-1 (n = 5). T-test. Mean ± SEM.∗p < 0.05, ∗∗p < 0.01.(C) Protein levels of IL-27 in lung tissues, nasal washes and serum of mice determined by ELISA (n = 3–4). T-test. Mean ± SEM. ∗p < 0.05. CT, cholera toxin adjuvant.
Fig 2: IL-27 promotes the activation of DCs stimulated by SPY1 through STAT3 and NF-κB signaling pathways(A) BMDC from WT and IL-27Rα KO mice were examined for (A) mRNA levels of IL-6, IL-1β, and IL-23A (n = 3). One-way ANOVA. Mean ± SEM.∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.(B) Protein (ELISA) levels of IL-6, IL-1β, and TGF-β (n = 3). One-way ANOVA. Mean ± SEM.∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.(C) Western blotting to detect phosphorylation states of STAT3 and NF-κB.(D) Relative densitometric intensity was determined for phosphorylated (p) -STAT3 and NF-κB and then normalized to levels of β-actin (n = 3). One-way ANOVA. Mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.
Fig 3: IL-27 inhibits the production of CD4+ memory cells during immunization with SPY1 vaccine(A) Representative flow cytometric plots showing the proportion of CD4+ memory cells in the indicated experimental groups.(B) Proportion and numbers of CD4+ memory cells in the indicated groups as assessed by flow cytometry (n = 4). T-test. Mean ± SEM.∗p < 0.05, ∗∗p < 0.01.(C) Levels of phosphorylated STAT3 (Y705) in WT SPY1 and KO SPY1 groups assessed by flow cytometry (n = 4). T-test. Mean ± SEM.∗p < 0.05.
Fig 4: Increased IL-27 production after ICH. a Photograph of representative gels demonstrating temporal changes of IL-27 p28 and EBI3 mRNA in the ICH-affected corpus striatum, at 0 h (sham control) and 1 h to 14 days after ICH in SD rats, which was assessed using RT-PCR, and (a, right panel) a bar graph of densitometrical quantitation. GAPDH was used as an internal control. The data were calculated as mean ± SEM (n = 4). b Bar graph of IL-27 p28 protein levels in CSF in naïve rats and in rats at 3, 24, and 48 h after ICH. The data were calculated as mean ± SEM (n = 3/time point). c Bar graph showing timecourse of IL-27 p28 protein levels in blood serum at 1 h to 21 days after ICH in C57BJ6 mice. The data were expressed as mean ± SEM (n = 5). d Photograph of a representative gel demonstrating temporal changes in IL-27 p28 and EBI3 mRNA in the spleen of rats subjected to ICH, assessed using RT-PCR, and (d, right panel) a bar graph of densitometrical quantitation. GAPDH was used as an internal control. The data were calculated as mean ± SEM (n = 4). *p ≤ 0.05, compared with the Sham group (0 h) for all the panels. The p-value in this figure was generated using one-way ANOVA followed by Newman–Keuls post-test
Fig 5: Crystal structures of the mouse IL-27 in complex with IL-27Rα and human IL-27 in complex with SRF388Fab(A) Overview of the IL-12 family of cytokines and their receptors. Immunoglobin (Ig) domains are shown as ovals with thick black outline. The cytokine-binding homology region (CHR) consisting of tandem fibronectin type III domains (FNIII) is shown with a double line in the upper domain and a single line in the lower domain. For IL-35 signaling complexes comprising gp130/gp130, IL-12Rβ2/IL-12Rβ2, and IL-27Rα/IL-12Rβ2 have also been described (Pylayeva-Gupta, 2016).(B) Comparison of the signaling activity of the recombinant mIL-27 (used for crystallization), recombinant single chain mouse IL-27, mIL-27sc (used for BLI), and commercially produced recombinant single chain mouse IL-27 from BioLegend, mIL-27scBL. STAT1 and STAT3 activity was measured in CD8+ T cells by flow cytometry upon stimulation with increasing concentrations of mIL-27. n = 3 technical replicates/data points, with error bars indicating SEM. These data are representative of two independent experiments with splenocytes from two distinct mice.(C) Chromatogram of the mIL-27:mIL-27Rα:Nb5 complex from the Superdex200 increase column. Coomassie-stained TGX gel run under denaturing conditions depicts the complex used for the crystallographic trials. Western blot of the same sample with antibodies specific to the respective subunits run in parallel is depicted on the right. Full blot is available in Figure S1B.(D) Kinetic binding profiles of hIL-27-SRF388 interaction characterized by the BLI. Anti-human IgG Fc (AHC) biosensors were used to immobilize SRF388 followed by binding measurements in different concentrations of hIL-27. One biosensor was used as a reference channel for background subtraction. Data traces (black) were fitted using a 1:1 interaction model (red) to quantify the kinetics (ka, kd) and binding affinity (KD) of the interactions. Data were analyzed with Octet Data Analysis software v10.0.1.7 (ForteBio). Data presented represent one experiment performed using optimized assay conditions. Additional BLI experiments were conducted; however, the kd exceeded the limit for dissociation. MSD solution-phase studies were used to confirm the BLI measurements (see STAR methods for additional detail).(E) Cartoon representation of the mIL-27:mIL-27Rα:Nb5 crystal structure. Nanobody 5 used as a crystallization adjuvant is shown in gray surface representation.(F) Cartoon representation of the hIL-27:SRF388Fab crystal structure. Inhibiting antibody SRF388Fab is shown in surface representation with light chain (LC) in magenta and heavy chain (HC) in light pink. Related to Figures S1–S3.
Supplier Page from BioLegend for Recombinant Mouse IL-27 (carrier-free)